While both feladilimab and PD-1 blockade demonstrated modest monotherapeutic effects, the combination of feladilimab and pembrolizumab resulted in enhanced tumor control relative to the monotherapies, though this was not statistically significant (Fig. 4H). Here, PDCD1 is linked to neoplasm.